pharam consultant
Jun 02, 2020
Eli Lilly’s COVID-19 Antibody trial; Approval for Oriahnn; Gilead’s Remdesivir Clinical Trials result; Russia approves Avifavir to treat Covid-19
Eli Lilly and AbCellera announced the dosing of the patients suffering from COVID-19 with antibody candidate - LY-CoV555. LY-CoV555 is a neutralizing IgG1 monoclonal antibody (mAb) that targets the spikes of the proteins of SARS-CoV-2. So far, COVID-19 has taken the lives of more than 372,000 people g...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
